Literature DB >> 33441083

The feasibility of new HPV/DNA test as a primary cervical cancer screening method among 35- years- old ever-married women in Kalutara district; a cross-sectional study.

K C M Perera1, N Mapitigama2, Htcs Abeysena3.   

Abstract

BACKGROUND: Cervical cancer is the second commonest female cancer in Sri Lanka. Two major drawbacks of the present cervical cancer screening programme are the suboptimal sensitivity of the pap smear and the low coverage. The objective of the study is to determine the feasibility of a new HPV/DNA test among 35 -years -old ever-married women in a district of Sri Lanka.
METHOD: A community based descriptive cross-sectional study was conducted from 1stof July 2018 to 30th November 2018 in the public health divisions called Medical Officer of Health (MOH) areas of Kalutara district. The study population is comprised of ever-married women 35 years of age. Three women from each cluster (n = 413) were selected by consecutive sampling. A total of 918 women were recruited. HPV/DNA cervical specimen collection (n = 822) was carried out. Cervical specimens were tested by two cytoscreeners with the cobas 4800 PCR based screening machine. Clients' perceptions and prevalence were assessed. The follow-up of women with positive HPV/DNA screening results was carried out. The operational and technical feasibility of the screening test were assessed. Data entry was done by using the statistical package IBM SPSS version 20.
RESULTS: Overall response rate was 91.1% (n = 836). Clients' perception was highly positive for HPV/DNA screening test procedure (99.9%, n = 821) and 99.6% (n = 819) of clients had mentioned that the HPV/DNA screening test is worthwhile to be incorporated into the National Cervical Cancer Screening program. The prevalence of HPV was 6.2% (95%CI: 6.18-6.22%). The coverage of the HPV/DNA screening was 89.5%(n = 822). Invalid results reported were 0.12% (n = 1). The percentage of HPV/DNA test positive women who underwent pap test within 3 months of the initial screening was 100% (n = 51), while the percentage of women who attempted to get a colposcopy within the 1 month of referral was 86.7% (n = 13).
CONCLUSIONS: HPV/DNA test implementation as a primary cervical cancer screening method is feasible among the 35- year age cohort of ever- married women in Kalutara district. It is necessary to further attempt alternative methods of cobas 4800 HPV/DNA test, which would be much suitable for resource-limited settings.

Entities:  

Keywords:  Cervical cancer; Feasibility; HPV/DNA test; Implementation; Screening

Mesh:

Substances:

Year:  2021        PMID: 33441083      PMCID: PMC7805031          DOI: 10.1186/s12889-021-10190-4

Source DB:  PubMed          Journal:  BMC Public Health        ISSN: 1471-2458            Impact factor:   3.295


  11 in total

1.  High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study.

Authors:  Mark H Stoler; Thomas C Wright; Abha Sharma; Raymond Apple; Karen Gutekunst; Teresa L Wright
Journal:  Am J Clin Pathol       Date:  2011-03       Impact factor: 2.493

2.  Prevalence and Risk Factors for Genital Human Papillomavirus Infections Among Women in Southwest Nigeria.

Authors:  Y T Nejo; D O Olaleye; G N Odaibo
Journal:  Arch Basic Appl Med       Date:  2018-05-04

3.  The acceptability of a self-lavaging device compared to pelvic examination for cervical cancer screening among low-income women.

Authors:  Heidi E Jones; Karen Brudney; Dorothy J Sawo; Rafael Lantigua; Carolyn L Westhoff
Journal:  J Womens Health (Larchmt)       Date:  2012-08-20       Impact factor: 2.681

Review 4.  Self-collected samples for testing of oncogenic human papillomavirus: a systematic review.

Authors:  Donna E Stewart; Anna Gagliardi; Mary Johnston; Robbi Howlett; Paula Barata; Nancy Lewis; Thomas Oliver; Verna Mai
Journal:  J Obstet Gynaecol Can       Date:  2007-10

5.  Pad - a new self-collection device for human papillomavirus.

Authors:  S R Kim; S Y Song; D S Kim; J-W Lee; B-G Kim; D-S Bae; E S Song; H J Joo
Journal:  Int J STD AIDS       Date:  2007-03       Impact factor: 1.359

6.  Mouthwash as a low-cost and safe specimen transport medium for human papillomavirus DNA testing of cervicovaginal specimens.

Authors:  Philip E Castle; Mark Sadorra; Francisco A R Garcia; Allison P Cullen; Attila T Lorincz; Amy L Mitchell; Denise Whitby; Ronald Chuke; Janet R Kornegay
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-04       Impact factor: 4.254

7.  Asia oceania guidelines for the implementation of programs for cervical cancer prevention and control.

Authors:  Hextan Y S Ngan; Suzanne M Garland; Neerja Bhatla; Sonia R Pagliusi; Karen K L Chan; Annie N Y Cheung; Tang-Yuan Chu; Efren J Domingo; You Lin Qiao; Jong Sup Park; Eng Hseon Tay; Wisit Supakarapongkul
Journal:  J Cancer Epidemiol       Date:  2011-04-13

8.  Stability Study of Cervical Specimens Collected by Swab and Stored Dry Followed by Human Papillomavirus DNA Detection Using the cobas 4800 Test.

Authors:  Chun-Qing Lin; Xi Zeng; Jian-Feng Cui; Guang-Dong Liao; Ze-Ni Wu; Qian-Qian Gao; Xun Zhang; Xiu-Zhang Yu; Wen Chen; Ming-Rong Xi; You-Lin Qiao
Journal:  J Clin Microbiol       Date:  2016-12-07       Impact factor: 5.948

9.  Self-sampling for human papillomavirus DNA detection: a preliminary study of compliance and feasibility in BOLIVIA.

Authors:  Pedro Surriabre; Gustavo Allende; Marcela Prado; Leyddy Cáceres; Diego Bellot; Andrea Torrico; Karina Ustariz; Shirley Rojas; Jaime Barriga; Pamela Calle; Ligia Villarroel; Rosse Mary Yañez; Marc Baay; Patricia Rodriguez; Véronique Fontaine
Journal:  BMC Womens Health       Date:  2017-12-22       Impact factor: 2.809

10.  Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline.

Authors:  Mark Schiffman; Gary Clifford; Franco M Buonaguro
Journal:  Infect Agent Cancer       Date:  2009-06-01       Impact factor: 2.965

View more
  1 in total

1.  Lab-on-chip assay of tumour markers and human papilloma virus for cervical cancer detection at the point-of-care.

Authors:  Benjamin W Wormald; Nicolas Moser; Nandita M deSouza; Katerina-Theresa Mantikas; Kenny Malpartida-Cardenas; Ivana Pennisi; Thomas E J Ind; Katherine Vroobel; Melpomeni Kalofonou; Jesus Rodriguez-Manzano; Pantelis Georgiou
Journal:  Sci Rep       Date:  2022-05-24       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.